Other Scandinavian College of Neuropsychopharmacology annual congress
09-06-2023 4:00 pm Add to iCal
Welcome to Participate in the SCNP Annual Congress, the days are filled with information about the latest research.
Registration is possible via the website https://scnp.org. Registration fee : DKK 3495.
The fee includes access to all sessions, coffee and lunches. Members of SCNP receive a discount of DKK 500. You can apply for membership on the website.
Location and accommodation
The meeting will take place in Biomedicum at Karolinska Institutet, Stockholm, Sweden.
See more details on the website, where accommodation also can be booked.
Selected topics and speakers
- Future therapies for Alzheimer’s disease
Lars Lannfelt, Uppsala University (Sweden)
- Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder
Susanne Bejerot, Örebro University (Sweden)
- Cannabis — The Good, The Bad and the Ugly in Relation to Psychiatric Disorders
Yasmin Hurd, Icahn School of Medicine at Mount Sinai (USA)
- Treatment Strategies for ADHD and Co-occurring Substance Use/Use Disorders
Frances Levin, Columbia University (USA)
- Psychedelics in depression – opportunities and challenges
Ole Andreassen, Oslo (Norway)
- Targeting Brain Kynurenic Acid for Cognitive Improvement
Robert Schwarcz, University of Maryland (USA)
- Suicide prevention- how to turn the tide?
Merete Nordentoft, University of Copenhagen (Denmark)
- Management of treatment-resistant depression: old ideas (& new)
Elias Eriksson, Gothenburg University (Sweden)
- SCNP Young Scientist Symposium (SCNP Award)
Speakers selected based on competition
You can find the more detailed program here.
SCNP was founded in Copenhagen in 1959, and has since been a major player in research, innovation and education related to medical psychiatric treatment in the Nordic countries: Denmark, Sweden, Norway, Iceland and Finland. Many notable observations and studies has been carried out by the SCNP and its members, e.g. the discovery and development of the first SSRI antidepressants. Today SCNP and its journal, 'Acta Neuropsychiatrica' , continues these proud traditions.